1. Home
  2. ADI vs VRTX Comparison

ADI vs VRTX Comparison

Compare ADI & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADI
  • VRTX
  • Stock Information
  • Founded
  • ADI 1965
  • VRTX 1989
  • Country
  • ADI United States
  • VRTX United States
  • Employees
  • ADI N/A
  • VRTX N/A
  • Industry
  • ADI Semiconductors
  • VRTX EDP Services
  • Sector
  • ADI Technology
  • VRTX Technology
  • Exchange
  • ADI Nasdaq
  • VRTX Nasdaq
  • Market Cap
  • ADI 115.2B
  • VRTX 96.6B
  • IPO Year
  • ADI 1972
  • VRTX 1991
  • Fundamental
  • Price
  • ADI $234.39
  • VRTX $434.51
  • Analyst Decision
  • ADI Buy
  • VRTX Buy
  • Analyst Count
  • ADI 22
  • VRTX 26
  • Target Price
  • ADI $270.00
  • VRTX $489.17
  • AVG Volume (30 Days)
  • ADI 3.5M
  • VRTX 1.4M
  • Earning Date
  • ADI 11-25-2025
  • VRTX 11-03-2025
  • Dividend Yield
  • ADI 1.70%
  • VRTX N/A
  • EPS Growth
  • ADI 18.69
  • VRTX N/A
  • EPS
  • ADI 3.93
  • VRTX 14.22
  • Revenue
  • ADI $10,386,795,000.00
  • VRTX $11,723,300,000.00
  • Revenue This Year
  • ADI $17.28
  • VRTX $10.95
  • Revenue Next Year
  • ADI $13.28
  • VRTX $9.55
  • P/E Ratio
  • ADI $59.12
  • VRTX $30.01
  • Revenue Growth
  • ADI 7.08
  • VRTX 10.33
  • 52 Week Low
  • ADI $158.65
  • VRTX $362.50
  • 52 Week High
  • ADI $258.13
  • VRTX $519.68
  • Technical
  • Relative Strength Index (RSI)
  • ADI 48.56
  • VRTX 58.04
  • Support Level
  • ADI $224.25
  • VRTX $418.53
  • Resistance Level
  • ADI $235.28
  • VRTX $442.22
  • Average True Range (ATR)
  • ADI 6.46
  • VRTX 12.75
  • MACD
  • ADI -0.19
  • VRTX -0.39
  • Stochastic Oscillator
  • ADI 53.75
  • VRTX 77.88

About ADI Analog Devices Inc.

Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: